Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419963 · ClinicalTrials.gov registry record · NA
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
A NA study of IBS and Diarrhoea Predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02419963: Completed NA study of IBS and Diarrhoea Predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
NCT02419963 is a NA study of IBS and Diarrhoea Predominant Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02419963, a NA study of IBS and Diarrhoea Predominant Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.
Primary Outcome
2 blood vials will be drawn during the flexible sigmoidoscopy or colonoscopy procedure, and serotonin levels will be drawn from one of these blood samples.
Conditions Studied
Interventions
- OTHER Blood Sample
- PROCEDURE endoscopy for tissue biopsy
- OTHER Stool Sample
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-12-12 |
| Phase | NA |
What the finished NCT02419963 record still lists
NCT02419963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with IBS appearing as the primary indexed condition, and to 3 interventions - of which Blood Sample is the first listed.
NCT02419963 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02419963 about?
NCT02419963 is a clinical study titled "Analyzing IBS to Identify Biomarkers and Microbiome Signatures". Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host...
What is the current status of trial NCT02419963?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2015-05. Estimated completion is 2016-12-12.
What conditions does trial NCT02419963 study?
This clinical trial studies the following conditions: IBS, Diarrhoea Predominant Irritable Bowel Syndrome.
What interventions are being tested in trial NCT02419963?
The interventions under investigation include: Blood Sample (OTHER), endoscopy for tissue biopsy (PROCEDURE), Stool Sample (OTHER).
Who is sponsoring clinical trial NCT02419963?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02419963 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IBS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02419963's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia